Article
siRNA-based Therapeutic Candidate Targeting PRDM2 for Inhibition of Lung Cancer Progression
2025-02-08
Abstract excerpt
Lung cancer is the leading cause of tumor-related fatalities worldwide. The current precision therapies are effective but target only those molecules that are impacted in a minority of lung cancer patients. Positive Regulatory Domain 2 (PRDM2), a member of the PRDM gene family, also known as Retinoblastoma Interacting Zinc finger (RIZ) protein. RIZ is found to be misregulated in more than 60% of lung cancer patien...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9c4261dc-6105-516f-afcf-583d6776e0ab
- DOI
- 10.1101/2025.02.06.636957
